稳定表达外源性p16基因肺癌A549细胞株的建立及鉴定

为构建稳定表达外源性抑癌基因p16的肺癌A549细胞株,用脂质体介导的基因转染方法,借助真核质粒表达载体（pcDNA3)。将抑癌基因p16转移入此基因缺失的人肺癌细胞株A549细胞中,经G418筛选,获得稳定表达的细胞克隆,用逆转录聚合酶链反应（RT-PCR）及免疫组织化学鉴定p16基因的表达,同时对克隆细胞分泌蛋白进行活性检测。结果显示转染p16基因的A549细胞中可以检测到p16mRNA及蛋白的表达,说明建立的p16真核表达载体能在肺肿瘤细胞中分泌表达蛋白,表达P16抑癌蛋白的A549细胞株的建立有助于研究抑癌基因p16在肺癌发生中的作用。     

高表达精脒/精胺N1-乙酞基转移酶对人肺癌A549细胞株生长的影响

旨在研究人精脒/精胺N1-乙酰基转移酶(spermidine/spermine N1-acetyltransferase,SSAT)高表达对人肺癌A549细胞生长的影响。以pCR2.1-SSAT质粒为模板,PCR法扩增人SSAT基因并克隆至pcDNA3.1表达载体。重组质粒转染A549细胞后,RT-PCR法和Western blotting法筛选SSAT高表达的细胞株。MTT法检测细胞增殖,流式细胞仪检测细胞周期。成功构建pcDNA3.1-SSAT重组质粒,用该质粒转染A549细胞后,筛选获得稳定高表达SSAT的细胞株。SSAT高表达导致细胞生长抑制,S期细胞减少和自发性凋亡细胞增多。结果显示,稳定高表达SSAT可在A549肺癌细胞中部分模拟多胺类似物类抗癌药物的药理活性,导致瘤细胞生长抑制和细胞凋亡。     

HPV-16早期基因E1在果蝇细胞S2中的表达和鉴定

目的:在果蝇S2细胞中表达人乳头瘤病毒16型(HPV-16)E1。方法:PCR扩增HPV-16 E1全长,将PCR产物连接至pMD18-T并测序鉴定,继而将HPV-16 E1构建至果蝇表达载体pMT/Bip/V5-HisA中。大量提取pMT/Bip/V5/His-E1重组表达载体并与筛选质粒pCoBlast共转染果蝇S2细胞,经杀稻瘟菌素(Blasticidin S)筛选获得具有抗性的稳定转染S2细胞。提取稳转S2细胞基因组DNA,PCR鉴定S2细胞中整合的E1。以终浓度为5μmol/L CdCl2诱导表达,收集上清进行SDS-PAGE及Western blot鉴定。结果:双酶切及测序结果显示HPV-16 E1基因已克隆人重组质粒pMT/Bip/V5-E1,PCR和Western blot结果表明HPV-16 E1基因已整合至果蝇S2细胞基因组并稳定表达。结论:获得HPV-16 E1转染的果蝇S2细胞株,该细胞株可持续稳定表达E1蛋白。     

pEGFP-HPV16E7重组融合蛋白质粒的构建及其表达

应用基因重组技术,构建增强绿色荧光蛋白(EGFP)与人乳头瘤病毒16型E7(HPV16E7)的重组融合表达质粒,经限制性内切酶酶切鉴定和PCR分析后,用基因转染技术将其导入小鼠肝癌细胞,荧光显微镜下观察融合蛋白的表达.酶切鉴定和PCR分析证实重组质粒中插入目的基因片段的大小、方向和插入位点均正确,在转染的小鼠肝癌细胞中观察到绿色荧光蛋白的表达.构建的pEGFP-HPV16E7融合表达质粒能直观地反映转染细胞中EGFP-HPV16E7融合蛋白的表达.由于转化率与表达率融为一体,故有利于对转染细胞的筛选,缩短转染细胞在体外的筛选的时间适用于对HPV16E7分子生物学特性、致瘤机理及APC提呈等的研究.为建立表达HPV16E7的实体瘤动物模型奠定了基础.     

人乳头瘤病毒l6型E6-E7融合蛋白真核表达载体的构建与鉴定

目的构建人乳头瘤病毒l6型(HPV16)E6-E7融合蛋白真核表达载体,为研究其基因疫苗免疫活性奠定实验基础。方法 PCR扩增HPV16 E6-E7基因片段,将其连接到真核表达载体pcDNA3.1(+),构建真核表达载体pcDNA3.1(+)/HPV16 E6-E7,双酶切及测序鉴定。将质粒转染HeLa细胞,RT-PCR鉴定E6-E7基因在HeLa细胞中的表达。提取质粒免疫小鼠,利用免疫组化方法检测在其肌肉组织中的表达。结果成功构建了真核表达载体pcDNA3.1(+)/HPV16 E6-E7;在转染pcDNA3.1(+)/HPV16 E6-E7的细胞中检测到HPV16 E6-E7基因。在免疫该质粒的小鼠肌肉组织中可以检测到该质粒的蛋白表达。结论成功的构建的了真核表达载体pcDNA3.1(+)/HPV16 E6-E7,该载体能在HeLa细胞内以及小鼠骨骼肌细胞内有效表达。     

pEGFP—HPV16E7重组融合蛋白质粒的构建及其表达

应用基因重组技术,构建增强绿色荧光蛋白(EGFP)与人乳头瘤病毒16型E7(HPV16E7)的重组融合表达质粒,经限制性内切酶酶切鉴定和PCR分析后,用基因转染技术将其导入小鼠肝癌细胞,荧光显微镜下观察融合蛋白的表达。酶切鉴定和PCR分析证实重组质粒中插入目的基因片段的大小、方向和插入位点均正确,在转染的小鼠肝癌细胞中观察到绿色荧光蛋白的表达。构建的pEGFP-HPV16E7融合表达质粒能直观地反映转染细胞中EGFP-HPV16E7融合蛋白的表达。由于转化率与表达率融为一体,故有利于对转染细胞的筛选,缩短转染细胞在体外的筛选的时间适用于对：HPV16E7分子生物学特性．致瘤机理及APC提呈等的研究。为建立表达HPV16E7的实体瘤动物模型奠定了基础。     

外源EGFP基因在肿瘤细胞中的稳定表达

通过将增强型绿色荧光蛋白（EGFP）基因转染到人肺腺癌细胞（A549）内,建立以EGFP为探针的体外抗癌药物细胞株。使用电穿孔法导入EGFP基因到A549细胞;然后用G418筛选以及梯度稀释法筛选出EGFP高度表达的细胞株。初步建立稳定表达绿色荧光蛋白的人肺癌细胞株。     

shRNA抑制宫颈癌Hela细胞株HPV18 E6、E7基因表达的研究

应用短发夹RNA(Short hairpin RNA,shRNA)表达载体抑制宫颈癌Hela细胞株HPV18 E6、E7基因的表达。应用已鉴定的shRNA表达载体pHPV1、pHPV2转染Hela细胞,G418筛选阳性细胞,建立稳定转染细胞株;倒置荧光显微镜检测转染情况;提取细胞内总RNA,RT-PCR方法检测HPV18 E6、E7 mRNA;WesternBlot检测HPV18 E6、E7蛋白表达的变化;采用灰度分析软件对PCR扩增条带与蛋白质条带进行灰度分析。pHPV1实验组细胞内HPV18 E6、E7 mRNA含量分别为阴性对照组的31%、38%,E6、E7蛋白分别为阴性对照组的37%、31%;pHPV2实验组细胞内HPV18 E6、E7 mRNA含量分别为阴性对照组的54%、77%,E6、E7蛋白分别为阴性对照组的52%、83%。pHPV1、pHPV2表达载体能抑制Hela细胞HPV18 E6、E7的表达,针对外显子区434-452的pHPV1抑制作用更强。     

人乳头瘤病毒16型E7过表达细胞的鉴定及其迁移效应的影响

鉴定人乳头瘤病毒16型早期蛋白7(HPV16E7)过表达细胞及其迁移效应的影响,为后续基于HPV16E7靶向分子作用机制的研究奠定工作基础.脂质体转染法将本室保存的pcDNA3.1-HPV16E7重组真核表达质粒分别转染人胚肾293T细胞(HPV16型DNA阴性)、宫颈癌SiHa细胞株(HPV16 DNA阳性),转染48 h后收集细胞,提取RNA,RT-PCR扩增相应的目的基因,Western Blotting和间接免疫荧光实验检测HPV16E7目的蛋白在细胞中的表达.转染24h的细胞进行细胞划痕和Transwell实验,检测过表达细胞迁移行为的变化.RT-PCR结果显示:分别从E7质粒转染的293T、SiHa细胞的cDNA中,均可扩增到250 bp的目的条带;Western Blotting分析结果显示:以HPV16E7单克隆抗体为检测抗体,转染细胞的裂解液中均能在相对分子质量(Mr)约为15 000处出现特异性目的条带;间接免疫荧光结果显示:转染细胞中均能检测到目的绿色荧光,且分布于胞浆及细胞核周围;细胞划痕和Transwell实验结果显示:转染E7细胞的迁移效应显著提高.本研究证实了 HPV16E7转染细胞后可成功表达,且过表达细胞明显促进了细胞迁移行为,为后续基于HPV16E7迁移相关分子机制及靶向干预等研究奠定了前期工作基础.     

稳定高表达人ERP57基因A549细胞株的建立及其对CRT表达的影响

建立稳定高表达人ERP57蛋白的A549细胞株,并观察对CRT表达的影响。采用巢式RT-PCR从人非小细胞肺腺癌A549细胞总RNA中克隆人ERP57 cDNA,构建ERP57真核表达质粒(pcDNA3.1(+)/ERP57)脂质体转染A549细胞。经G418筛选,获得高表达人ERP57蛋白的A549细胞株。通过Western blotting检测细胞中ERP57及CRT蛋白表达情况。成功获得稳定高表达ERP57蛋白的人A549细胞株,CRT表达量无明显改变。成功获得稳定高表达ERP57蛋白的人A549细胞株,证实细胞中高表达ERP57对CRT表达量无明显影响。     

Relationships of the Col plasmids E2, E3, E4, E5, E6, and E7: Restriction mapping and colicin gene fusions

Thirteen ColE plasmids representing the E2-E7 types have been compared by restriction mapping. Over 80% of their restriction sites were found to be similarly positioned, indicating that these plasmids share a common structure. Three variants are ColE2-CA42 and ColE7-K317, both of which contain 1.8-kb DNA segments in place of a 2.5-kb segment common to the other plasmids, and ColE6-CT14, which has an additional 5.0-kb DNA segment compared to the other plasmids. The colicin (col), immunity (imm), and colicin release (hic) genes of these plasmids have been localized to regions corresponding to those known for ColE3-CA38 and ColE2-P9, with the imm and hic genes adjacent to the 3' end of the col gene. Active colicin is produced from hybrid col genes containing 5' and 3' ends from different E-type plasmids. The 3'-termini of the fused col genes specify the colicin type.     

Negative regulation of the bovine papillomavirus E5, E6, and E7 oncogenes by the viral E1 and E2 genes.

Papillomaviruses induce benign squamous epithelial lesions that infrequently are associated with uncontrolled growth or malignant conversion. The virus-encoded oncogenes are clearly under negative regulation since papillomaviruses can latently infect cells and since different levels of viral oncogene expression are seen within the layers of differentiating infected epitheliomas. We used bovine papillomavirus type 1 (BPV-1) to investigate the mechanisms involved in the negative regulation of transformation. We found that the following two distinct and interacting mechanisms negatively regulate BPV-1 transformation effected by virally encoded trans-acting factors: (i) E2 repressors suppress transformation by the E6 and E7 oncogenes, and (ii) E1 and the E2 transactivator suppress transformation by the E6, E7, and E5 oncogenes. These systems interact in that the E2 repressors function to relieve the transformation suppression effected by the E1 and E2 transactivator genes. A BPV-1 mutant that lacked E2 repressors and E1 had greatly augmented transformation capacity. Analysis of this mutant revealed that the enhanced transformation was due to expression of the E6 and E7 genes in the absence of E5, revealing a previously unappreciated potency and synergy for the BPV-1 E6 and E7 oncogenes.     

硬粒小麦 长穗偃麦草2E和4E附加系及E染色体传递

为探讨长穗偃麦草E染色体在硬粒小麦背景中的传递特点,利用染色体特异分子标记、基因组原位杂交(GISH)、非变性荧光原位杂交(ND FISH)等方法,对小偃麦8801(AABBEE)与硬粒小麦(AABB)杂交后代中选育的株系Du_No.2和Du_No.4进行了分析。结果表明：(1)分子标记检测株系Du_No.2及Du_No.4分别能扩增出长穗偃麦草2E、4E染色体特异条带。(2)GISH和ND FISH分析显示,株系Du_No.2和Du_No.4分别附加了1条2E和4E染色体,表明株系Du_No.2 和Du_No.4分别为硬粒小麦 长穗偃麦草2E和4E单体附加系。(3)2个株系的减数分裂过程观察发现,后期Ⅰ、Ⅱ和末期Ⅱ都有E染色体分离异常现象,且株系Du_No.2和 Du_No.4的异常率分别为22.24%和36.18%。(4)2个株系分别与硬粒小麦进行正反杂交的后代PCR分析表明, 2E和4E染色体经雄配子的传递率分别为4.41%和2.17%,而通过雌配子的传递率都为零,表明2E和4E染色体在硬粒小麦背景中能通过雄配子传递,但不通过雌配子的传递。该研究为创建全套硬粒小麦 长穗偃麦草双体附加系及代换系提供基础。     

Isolation of 19,20-dehydroprostaglandins E1 and E2 in human seminal fluid and further studies on 18,19-dehydroprostaglandins E1 and E2

Human seminal fluid was recently found to contain 18,19-dehydroprostaglandins E1 and E2 (E. H. Oliw, H. Sprecher, and M. Hamberg, (1986) J. Biol. Chem. 261, 2675-2683). In the present study, the cis and trans isomers of 18,19-dehydroprostaglandins E1 and E2 were prepared by incubation of microsomes of ram vesicular glands and glutathione with the precursor fatty acids, 8(Z),11(Z),14(Z),18(E/Z)-eicosatetraenoic acids, and 5(Z),8(Z),11(Z),14(Z),18(E/Z)-eicosapentaenoic acids, and used as references to characterize the 18,19-dehydroprostaglandins of human seminal fluid. Based on separation by reversed-phase high-performance liquid chromatography, capillary gas chromatography-mass spectrometry, and ozonolysis of the (-)-menthoxycarbonyl derivatives and on comparison with the authentic compounds, human seminal fluid was found to contain both the cis and trans isomers of 18,19-dehydroprostaglandins E1 and E2. Furthermore, human seminal fluid contained two related compounds, viz. 19,20-dehydroprostaglandins E1 and E2. The structures of these compounds were established by conversion into the corresponding prostaglandin B compounds, by mass spectrometric analysis and by chemical degradation by oxidative ozonolysis, which afforded, inter alia, 2(S)-hydroxy-adipic acid.     

Phosphatidylethanolamide derivatives of prostaglandins E1 and E2.

Prostaglandins E1 (PGE1) and E2 (PGE2) have been coupled with the amine group of phosphatidylethanolamine (PE) by means of dicyclohexylcarbodiimide. These complexes basically mimic the relaxant and contractile effects of the corresponding free prostaglandins (PGs) on various smooth muscle preparations, but exhibit a delayed onset of action and a lower affinity for the PG receptors. The complexes are comparable with the free, parent PGs, in their intrinsic activities. The same holds true for the effects on blood pressure and on the motility of the uterus in situ. The PGE2-PE complex is hydrolysed to release obviously free PGE2 by cell-free homogenates prepared from various tissues, but not by blood plasma. The PGE2-PE complex is immunologically indistinguishable from the free PGE2.